David Hildick Smith - What’s new: clinical data published and presented since last year
New clinical data for left atrial appendage occlusion therapy, presented & published in 2016. Includes a critical review of the Stroke Prevention section in the 2016 ESC Atrial Fibrillation guidelines.
Matthew Price - What’s new: cost effectiveness and health economics
Why might LAA occlusion therapy be cost effective, despite a high procedural cost? This presentation is an overview of the health economics data available for left atrial appendage closure therapy.
Per Wester - The neurologist's perspective: insights in AF-thromboembolic events prevention
The Neurologist point of view: review of the published evidence and the consensus on bleeding+stroke risk assessments in AF patients. when approaching antithrombotic therapy in AF patients. Includes uptake of the LAAO recommendation in the ESC guidelines and what that means to Neurologists. Many Cardiologists do not really know what Neurologist think and the reasoning. What it does it mean to the every day practice, and the annual number of ICH on NOAC or VKA for the average neurology practice?
Thorsten Lewalter - What's new: expert consensus statements - focus on Munich Consensus Paper
Driving factors and main considerations for the LAA occlusion consensus papers (including EHRA/EAPCI and others). This includes a summary of main recommendations, including training & proctoring. What does this document mean for the average implanting cardiologist and follow-up physician?
Xavier Freixa - What's new for LAA Occlusion in 2016; clinical data published and presented in 2015
Which data is published since January 2015? Includes papers on LAAO, but also key results from other stroke prevention trials and analysis. SHOW MORE
Ulf Landmesser - LAA occlusion: where are we compared to new drugs, AF ablation and emerging technologies?
Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing? Has the role of LAAO changed in the recent years? How does LAAO compare to the NOAC?
Gabriele Vicedomini - Practical implications of the EHRA/EAPCI consensus statement
Driving factors and main considerations for the LAA occlusion consensus paper = summary of main recommendations, including training & proctoring. What does this document mean for the average implanting cardiologist and follow-up physician?
DJ (Dhanunjaya) Lakkireddy - Protagonist. LAA occlusion is for (N)OAC in-tolerant patients only
Debate - Protagonist. LAA occlusion should be considered for (N)OAC in-tolerant patients primarily.